635 related articles for article (PubMed ID: 30878999)
1. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
Strugnell SA; Sprague SM; Ashfaq A; Petkovich M; Bishop CW
Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999
[TBL] [Abstract][Full Text] [Related]
2. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease.
Sprague SM; Silva AL; Al-Saghir F; Damle R; Tabash SP; Petkovich M; Messner EJ; White JA; Melnick JZ; Bishop CW
Am J Nephrol; 2014; 40(6):535-45. PubMed ID: 25572630
[TBL] [Abstract][Full Text] [Related]
3. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease.
Sprague SM; Crawford PW; Melnick JZ; Strugnell SA; Ali S; Mangoo-Karim R; Lee S; Petkovich PM; Bishop CW
Am J Nephrol; 2016; 44(4):316-325. PubMed ID: 27676085
[TBL] [Abstract][Full Text] [Related]
4. Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation.
Petkovich M; Melnick J; White J; Tabash S; Strugnell S; Bishop CW
J Steroid Biochem Mol Biol; 2015 Apr; 148():283-9. PubMed ID: 25446887
[TBL] [Abstract][Full Text] [Related]
5. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.
Ennis JL; Worcester EM; Coe FL; Sprague SM
J Nephrol; 2016 Feb; 29(1):63-70. PubMed ID: 25736620
[TBL] [Abstract][Full Text] [Related]
6. Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients.
Germain MJ; Paul SK; Fadda G; Broumand V; Nguyen A; McGarvey NH; Gitlin MD; Bishop CW; Csomor P; Strugnell S; Ashfaq A
BMC Nephrol; 2022 Nov; 23(1):362. PubMed ID: 36368937
[TBL] [Abstract][Full Text] [Related]
7. Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary Hyperparathyroidism.
Bishop CW; Strugnell SA; Csomor P; Kaiser E; Ashfaq A
Am J Nephrol; 2022; 53(6):446-454. PubMed ID: 35551374
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of High vs. Conventional Ergocalciferol Dose for Increasing 25-Hydroxyvitamin D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial.
Thimachai P; Supasyndh O; Chaiprasert A; Satirapoj B
J Med Assoc Thai; 2015 Jul; 98(7):643-8. PubMed ID: 26267985
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease.
Strugnell SA; Csomor P; Ashfaq A; Bishop CW
Kidney Dis (Basel); 2023 May; 9(3):206-217. PubMed ID: 37497207
[TBL] [Abstract][Full Text] [Related]
10. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
[TBL] [Abstract][Full Text] [Related]
11. Posterior urethral valves: Metabolic consequences in a cohort of patients.
Sarhan O; Nakshabandi Z; Alghanbar M; Alotay A; Sherif I; Whitehead C; El-Husseini A
J Pediatr Urol; 2015 Aug; 11(4):216.e1-6. PubMed ID: 26096436
[TBL] [Abstract][Full Text] [Related]
12. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial.
Alvarez JA; Law J; Coakley KE; Zughaier SM; Hao L; Shahid Salles K; Wasse H; Gutiérrez OM; Ziegler TR; Tangpricha V
Am J Clin Nutr; 2012 Sep; 96(3):672-9. PubMed ID: 22854402
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD.
Kalantar-Zadeh K; Hollenbeak CS; Arguello R; Snyder S; Ashfaq A
J Med Econ; 2020 Mar; 23(3):308-315. PubMed ID: 31726882
[No Abstract] [Full Text] [Related]
14. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
Hong YA; Lim JH; Kim MY; Kim Y; Yang KS; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550
[TBL] [Abstract][Full Text] [Related]
15. Disordered FGF23 and mineral metabolism in children with CKD.
Portale AA; Wolf M; Jüppner H; Messinger S; Kumar J; Wesseling-Perry K; Schwartz GJ; Furth SL; Warady BA; Salusky IB
Clin J Am Soc Nephrol; 2014 Feb; 9(2):344-53. PubMed ID: 24311704
[TBL] [Abstract][Full Text] [Related]
16. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects.
Martin KJ; Bell G; Pickthorn K; Huang S; Vick A; Hodsman P; Peacock M
Nephrol Dial Transplant; 2014 Feb; 29(2):385-92. PubMed ID: 24235081
[TBL] [Abstract][Full Text] [Related]
17. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study.
Chandra P; Binongo JN; Ziegler TR; Schlanger LE; Wang W; Someren JT; Tangpricha V
Endocr Pract; 2008; 14(1):10-7. PubMed ID: 18238736
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial.
Bleskestad IH; Bergrem H; Hartmann A; Godang K; Gøransson LG
BMC Nephrol; 2012 Jun; 13():49. PubMed ID: 22742720
[TBL] [Abstract][Full Text] [Related]
19. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.
Coburn JW; Maung HM; Elangovan L; Germain MJ; Lindberg JS; Sprague SM; Williams ME; Bishop CW
Am J Kidney Dis; 2004 May; 43(5):877-90. PubMed ID: 15112179
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and correlates of 25-hydroxyvitamin D deficiency in the Chronic Kidney Disease in Children (CKiD) cohort.
Kumar J; McDermott K; Abraham AG; Friedman LA; Johnson VL; Kaskel FJ; Furth SL; Warady BA; Portale AA; Melamed ML
Pediatr Nephrol; 2016 Jan; 31(1):121-9. PubMed ID: 26307635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
